Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction

T. I G van der Spoel; W. A. Gathier; S. Koudstaal; F. van Slochteren; S. Jansen Of Lorkeers; J. P G Sluijter; I. E. Hoefer; P. Steendijk; M. J M Cramer; P. A. Doevendans; E. van Belle; S. A J Chamuleau

doi:10.1007/s12265-015-9643-3

Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction

T. I G van der Spoel, W. A. Gathier, S. Koudstaal, F. van Slochteren, S. Jansen Of Lorkeers, J. P G Sluijter, I. E. Hoefer, P. Steendijk, M. J M Cramer, P. A. Doevendans, E. van Belle, S. A J Chamuleau^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Cardiac cell therapy is a strategy to treat patients with chronic myocardial infarction (MI). No consensus exists regarding the optimal cell type. First, a comparison between autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) on therapeutic efficacy after MI was performed. Next, the effect of repetitive, NOGA-guided transendocardial injection was determined via a crossover design. Nineteen pigs were allocated in three groups: (1) placebo (at 4 and 8 weeks), (2) MSC (followed by placebo at 8 weeks), or (3) BMMNC (followed by MSC at 8 weeks) delivery including a priming strategy to enhance MSC effect. At 4 weeks, ejection fraction (EF) was significantly improved after MSC injection and not by BMMNC injection. After 8 weeks, no difference was observed in EF between cell-treated groups demonstrating the positive systolic effect of MSC. This study showed that MSC rather than BMMNC injection improves systolic function in chronic MI.

Original language	English
Pages (from-to)	393-403
Number of pages	11
Journal	Journal of Cardiovascular Translational Research
Volume	8
Issue number	7
DOIs	https://doi.org/10.1007/s12265-015-9643-3
Publication status	Published - 2015

Keywords

Ischemic cardiomyopathy
Mesenchymal stem cell
Stem cells
Systolic function

Access to Document

10.1007/s12265-015-9643-3

autologousFinal published version, 5.55 MB

Cite this

van der Spoel, T. I. G., Gathier, W. A., Koudstaal, S., van Slochteren, F., Of Lorkeers, S. J., Sluijter, J. P. G., Hoefer, I. E., Steendijk, P., Cramer, M. J. M., Doevendans, P. A., van Belle, E., & Chamuleau, S. A. J. (2015). Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction. Journal of Cardiovascular Translational Research, 8(7), 393-403. https://doi.org/10.1007/s12265-015-9643-3

@article{616308fe954144559c82ed01d4df43c4,

title = "Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction",

abstract = "Cardiac cell therapy is a strategy to treat patients with chronic myocardial infarction (MI). No consensus exists regarding the optimal cell type. First, a comparison between autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) on therapeutic efficacy after MI was performed. Next, the effect of repetitive, NOGA-guided transendocardial injection was determined via a crossover design. Nineteen pigs were allocated in three groups: (1) placebo (at 4 and 8 weeks), (2) MSC (followed by placebo at 8 weeks), or (3) BMMNC (followed by MSC at 8 weeks) delivery including a priming strategy to enhance MSC effect. At 4 weeks, ejection fraction (EF) was significantly improved after MSC injection and not by BMMNC injection. After 8 weeks, no difference was observed in EF between cell-treated groups demonstrating the positive systolic effect of MSC. This study showed that MSC rather than BMMNC injection improves systolic function in chronic MI.",

keywords = "Ischemic cardiomyopathy, Mesenchymal stem cell, Stem cells, Systolic function",

author = "{van der Spoel}, {T. I G} and Gathier, {W. A.} and S. Koudstaal and {van Slochteren}, F. and {Of Lorkeers}, {S. Jansen} and Sluijter, {J. P G} and Hoefer, {I. E.} and P. Steendijk and Cramer, {M. J M} and Doevendans, {P. A.} and {van Belle}, E. and Chamuleau, {S. A J}",

year = "2015",

doi = "10.1007/s12265-015-9643-3",

language = "English",

volume = "8",

pages = "393--403",

journal = "Journal of Cardiovascular Translational Research",

issn = "1937-5387",

publisher = "Springer New York",

number = "7",

}

van der Spoel, TIG, Gathier, WA, Koudstaal, S, van Slochteren, F, Of Lorkeers, SJ, Sluijter, JPG, Hoefer, IE, Steendijk, P, Cramer, MJM, Doevendans, PA, van Belle, E & Chamuleau, SAJ 2015, 'Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction', Journal of Cardiovascular Translational Research, vol. 8, no. 7, pp. 393-403. https://doi.org/10.1007/s12265-015-9643-3

Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction. / van der Spoel, T. I G; Gathier, W. A.; Koudstaal, S. et al.
In: Journal of Cardiovascular Translational Research, Vol. 8, No. 7, 2015, p. 393-403.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction

AU - van der Spoel, T. I G

AU - Gathier, W. A.

AU - Koudstaal, S.

AU - van Slochteren, F.

AU - Of Lorkeers, S. Jansen

AU - Sluijter, J. P G

AU - Hoefer, I. E.

AU - Steendijk, P.

AU - Cramer, M. J M

AU - Doevendans, P. A.

AU - van Belle, E.

AU - Chamuleau, S. A J

PY - 2015

Y1 - 2015

N2 - Cardiac cell therapy is a strategy to treat patients with chronic myocardial infarction (MI). No consensus exists regarding the optimal cell type. First, a comparison between autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) on therapeutic efficacy after MI was performed. Next, the effect of repetitive, NOGA-guided transendocardial injection was determined via a crossover design. Nineteen pigs were allocated in three groups: (1) placebo (at 4 and 8 weeks), (2) MSC (followed by placebo at 8 weeks), or (3) BMMNC (followed by MSC at 8 weeks) delivery including a priming strategy to enhance MSC effect. At 4 weeks, ejection fraction (EF) was significantly improved after MSC injection and not by BMMNC injection. After 8 weeks, no difference was observed in EF between cell-treated groups demonstrating the positive systolic effect of MSC. This study showed that MSC rather than BMMNC injection improves systolic function in chronic MI.

AB - Cardiac cell therapy is a strategy to treat patients with chronic myocardial infarction (MI). No consensus exists regarding the optimal cell type. First, a comparison between autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) on therapeutic efficacy after MI was performed. Next, the effect of repetitive, NOGA-guided transendocardial injection was determined via a crossover design. Nineteen pigs were allocated in three groups: (1) placebo (at 4 and 8 weeks), (2) MSC (followed by placebo at 8 weeks), or (3) BMMNC (followed by MSC at 8 weeks) delivery including a priming strategy to enhance MSC effect. At 4 weeks, ejection fraction (EF) was significantly improved after MSC injection and not by BMMNC injection. After 8 weeks, no difference was observed in EF between cell-treated groups demonstrating the positive systolic effect of MSC. This study showed that MSC rather than BMMNC injection improves systolic function in chronic MI.

KW - Ischemic cardiomyopathy

KW - Mesenchymal stem cell

KW - Stem cells

KW - Systolic function

UR - http://www.scopus.com/inward/record.url?scp=84941686872&partnerID=8YFLogxK

U2 - 10.1007/s12265-015-9643-3

DO - 10.1007/s12265-015-9643-3

M3 - Article

C2 - 26382088

AN - SCOPUS:84941686872

SN - 1937-5387

VL - 8

SP - 393

EP - 403

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

IS - 7

ER -

Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this